Norris Medicines Limited is an Indian pharmaceutical company specializing in **contract manufacturing** and **Loan License Manufacturing** for multinational and domestic pharmaceutical firms. Operating from its industrial base in **Ankleshwar, Gujarat**, the company is currently navigating a complex strategic transition aimed at reversing long-term revenue contraction through **operational restructuring**, **asset optimization**, and **international market expansion**. --- ### **Manufacturing Infrastructure & Quality Compliance** The company’s core value proposition lies in its established manufacturing footprint, which is being upgraded to meet stringent global regulatory standards. * **Production Facilities:** Operates **two manufacturing plants** located at the **GIDC Estate, Ankleshwar**. * **Regulatory Approvals:** Both facilities are **WHO GMP approved**, ensuring compliance with Good Manufacturing Practices. * **Sterile Injectables Upgrade:** The company recently **renovated its sterile injectable plant** to international standards. This modernization is specifically designed to attract higher order volumes from major global pharmaceutical players. * **African Market Entry:** In **December 2025**, the facility successfully completed an inspection by the **National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria**. The audit concluded with **zero critical observations**, providing a clear pathway for export growth into the African continent. --- ### **Financial Performance & Historical Trends** Norris Medicines operates in a **single business segment** (Pharmaceuticals). While the company has seen a recent uptick in quarterly performance, it faces a long-term challenge of declining scale and persistent losses. #### **Comparative Financial Summary** | Metric | FY 2024-25 (Audited) | FY 2023-24 (Audited) | FY 2022-23 (Audited) | | :--- | :--- | :--- | :--- | | **Total Turnover (incl. Other Income)** | **₹5.88 Crore** | **₹5.66 Crore** | **₹9.46 Crore** | | **Net Profit / (Loss)** | **(₹1.24 Crore)** | **(₹1.75 Crore)** | **(₹3.26 Crore)** | | **Export Income (FOB)** | — | **₹42.77 Lacs** | **₹19.83 Lacs** | | **Dividend** | **Nil** | **Nil** | **Nil** | #### **Recent Momentum** * **Revenue Contraction:** Net sales have declined from **₹16.27 crore** in **March 2019** to **₹5.82 crore** in **March 2025**. * **Q4 FY25 Performance:** A notable recovery was observed in the quarter ended **March 2025**, with sales rising to **₹2.72 crore** (compared to **₹1.49 crore** in Q4 FY24) and a narrowed net loss of **(₹0.23 crore)**. * **Export Growth:** Despite overall revenue pressure, export income grew significantly from **₹19.83 Lacs** to **₹42.77 Lacs** as of the **March 2024** reporting period. --- ### **Strategic Turnaround & Capital Mobilization** To address its financial position and "Going Concern" uncertainties, management is executing a multi-pronged stabilization strategy. #### **1. Capital Infusion & Debt Management** * **Borrowing Expansion:** The Board has sought shareholder approval to increase borrowing limits up to **₹20 Crores**. These funds are earmarked for **expansion, working capital, acquisitions, and debt refinancing**. * **Credit Facilities:** Current working capital is secured through **City Union Bank** via the hypothecation of current assets and an equitable mortgage of **Plot no. 802, GIDC Ankleswar**, backed by a **personal guarantee** from the **Managing Director**. #### **2. Asset & Cost Optimization** * **Divestment Mandate:** A proposal is in place to sell, lease, or dispose of non-core assets or undertakings valued up to **₹10 Crore** to improve liquidity and focus on core operations. * **Procurement Efficiency:** The company is implementing **economic bulk order quantity sourcing** and regular negotiations with key suppliers to mitigate rising raw material costs. #### **3. Market Diversification** * **Economies of Scale:** By expanding into international markets, the company aims to overcome **batch size issues** that hamper domestic profitability. * **Pricing Hedge:** Diversifying across different geographies is intended to offset stringent **governmental pricing controls** in the Indian domestic market. --- ### **Governance & Leadership Evolution** The company is undergoing a structural cleanup of its board and promoter group to align with **SEBI (LODR)** standards. * **Board Strengthening:** Appointment of **Ms. Sathya Venkatachalam** as a Non-Executive Independent Director (2024–2029) and **CS Priyanka Lohiya** as Company Secretary and Compliance Officer. * **Audit Oversight:** **M/s HSPN & Associates LLP** has been appointed as Secretarial Auditors for a five-year tenure (FY 2025-26 to FY 2029-30). * **Promoter Reclassification:** The company is processing a request from **Mr. Nimish Bhisma Thakore** (holding **<0.01%**) to move from the 'Promoter' to the 'Public' category, signaling a rationalization of the ownership structure. * **Executive Stability:** Remuneration for Executive Director **Mr. Vimal D. Shah** was revised to **₹24 Lakhs** effective October 2025 to ensure leadership continuity. --- ### **Critical Risk Factors & Regulatory Challenges** Investors should note significant headwinds regarding compliance, liquidity, and legal history. #### **Regulatory & Compliance Arrears** * **Unpaid Penalties:** As of late 2025, **₹2,96,180** remains outstanding for late filings of shareholding patterns and financial results. * **Listing Fees:** The company has failed to pay **Annual Listing Fees** for **FY 2025-26**, including interest arrears. * **Statutory Dues:** Auditors have flagged irregularities in depositing undisputed dues (Provident Fund, ESI, Income Tax, GST), with some arrears outstanding for over **six months**. * **Surveillance:** The company’s securities are currently under **Graded Surveillance Measures (GSM)** by the **BSE Limited**. #### **Legal & Operational Risks** * **MPID Act Litigation:** After a long-standing dispute dating back to **2001**, the company received a **favorable final order** on **November 19, 2025**, rendering the case infructuous and providing significant legal relief. * **BIFR Status:** The company remains protected under **BIFR Case No. 90/2004**. * **Leadership Turnover:** Recent exits include the **CFO (Mr. Iqubal Patel)** in February 2026 and Independent Director **Ms. Sathya Venkatachalam** in December 2025, presenting risks to management continuity. * **Going Concern:** Auditors continue to highlight material uncertainties regarding the company's ability to sustain operations given its **carried forward losses** and adverse financial position. #### **Market Risk Matrix** | Risk Category | Impact | | :--- | :--- | | **Input Costs** | Rising expenses related to **energy and manpower** impacting margins. | | **Competition** | Pressure from **generic and biosimilar** competitors and patent expirations. | | **Compliance Costs** | Ever-increasing costs to maintain international WHO/NAFDAC standards. | | **Insider Trading** | Flagged as **SDD Non-Compliant** for failing to implement required System Driven Disclosure software. |